Buy Chloroquine (Aralen) Online

How and where to order Aralen (Chloroquine Phosphate) 250 mg, 500 mg tablets or capsules online:

Shop:DISCOUNT MEDS - 10% discount coupon iQGmcrEh
Prices:from $0.56 per pill
Forms:250 mg, 500 mg capsules or tablets
Quantity:20-360 pills
Type:Chloroquine brand, Aralen generic
Payment:Visa, Mastercard, AmEx, Cryptocurrencies
Delivery:Regular airmail and express courier
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia

Indications and usage:

Aralen (Chloroquine Phosphate) is indicated for the:

  • Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale, and P.vivax.
  • Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present.
  • Treatment of extraintestinal amebiasis.

    Aralen does not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites.

    Limitations of use in malaria:

  • Do not use chloroquine tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure).
  • Do not use Aralen for malaria prophylaxis in areas where chloroquine resistance occurs, resistance to chloroquine is widespread in P. falciparum, and is reported in P.vivax.
  • Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale.

    Dosage and administration:

    The dosage of chloroquine phosphate is often expressed in terms of equivalent chloroquine base. Each 500 mg tablet of Aralen contains the equivalent of 300 mg chloroquine base. In infants and children the dosage is preferably calculated by body weight.

    Dosage forms and strengths:

    Aralen (Chloroquine Phosphate) tablets for oral use: 250 mg and 500 mg.


  • Use of Aralen (Chloroquine Phosphate) tablets for indications other than acute malaria is contraindicated in the presence of retinal or visual field changes of any etiology.
  • Use of this medication is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds.

    Warnings and precautions:

  • chloroquine-resistant malaria
  • treatment of exo-erythocytic forms of malaria
  • cardiac effects
  • hypoglycemia
  • retinopathy
  • central nervous system effects
  • muscular weakness
  • pediatric accidental ingestion
  • worsening of psoriasis and porphyria
  • hematological effects
  • auditory effects


    Signs and symptoms:

    Chloroquine is very rapidly and completely absorbed after ingestion. Toxic doses of chloroquine can be fatal. As little as 1 g may be fatal in children. Toxic symptoms can occur within minutes. The symptoms of overdosage may include nausea, vomiting, headache, drowsiness, visual disturbances, cardiovascular collapse, convulsions, hypokalemia, rhythm and conduction disorders including QT prolongation, torsades de pointes, ventricular tachycardia and ventricular fibrillation, followed by sudden potentially fatal respiratory and cardiac arrest. Immediate medical attention is required, as these effects may appear shortly after the overdose. Cases of extrapyramidal disorders have also been reported in the context of chloroquine overdose.


    Treatment is symptomatic and must be prompt with immediate evacuation of the stomach by emesis or gastric lavage followed by treatment with activated charcoal. Chloroquine (Aralen) overdose is a life-threatening emergency and should be managed with cardio-respiratory and hemodynamic support, monitoring of potassium along with management of arrhythmias and convulsions, as necessary. A patient who survives the acute phase and is asymptomatic should be closely observed until all clinical features of toxicity resolve.

    Side effects, adverse reactions:

    The most common adverse reactions have been identified during post-approval use of chloroquine or other 4-aminoqunoline compounds: maculopathy and macular degeneration, urticaria, nerve type deafness; tinnitus, sensorimotor disorders, hepatitis, increased liver enzymes, anorexia, nausea, vomiting, diarrhea, abdominal cramps, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pancytopenia, aplastic anemia, reversible agranulocytosis, thrombocytopenia, neutropenia, convulsions, mild and transient headache, polyneuropathy, psychosis, delirium, anxiety, agitation, insomnia, confusion, hallucinations, personality changes, depression, hypotension, electrocardiographic changes.

    Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    To report suspected side effects of Aralen (Chloroquine Phosphate) tablets, contact Sanofi pharmaceutical company or your local FDA.

    Drug interactions:

  • Antacids and kaolin: antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed.
  • Cimetidine: cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level. Concomitant use of cimetidine should be avoided.
  • Insulin and other antidiabetic drugs: as chloroquine may enhance the effects of a hypoglycemic treatment, a decrease in doses of insulin or other antidiabetic drugs may be required.
  • Arrhythmogenic drugs: there may be an increased risk of inducing ventricular arrhythmias if Chloroquine (Aralen) is used concomitantly with other arrhythmogenic drugs, such as amiodarone or moxifloxacin.
  • Ampicillin: in a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin. An interval of at least two hours between intake of ampicillin and chloroquine should be observed.
  • Cyclosporine: after introduction of chloroquine phosphate oral form, a sudden increase in serum cyclosporine level has been reported. Therefore, close monitoring of serum cyclosporine level is recommended and, if necessary, chloroquine should be discontinued.
  • Mefloquine: co-administration of chloroquine and mefloquine may increase the risk of convulsions. The blood concentrations of chloroquine and desethylchloroquine (the major metabolite of chloroquine, which also has antimalarial properties) were negatively associated with log antibody titers. Chloroquine taken in the dose recommended for malaria prophylaxis can reduce the antibody response to primary immunization with intradermal human diploid-cell rabies vaccine.
  • Praziquantel: in a single-dose interaction study, Aralen has been reported to reduce the bioavailability of praziquantel.
  • Tamoxifen: Concomitant use of chloroquine with drugs known to induce retinal toxicity such as tamoxifen is not recommended.

    Use in specific populations:


    Usage of chloroquine during pregnancy should be avoided except in the prophylaxis or treatment of malaria when the benefit outweighs the potential risk to the fetus. Radioactively tagged chloroquine administered intravenously to pregnant pigmented CBA mice passed rapidly across the placenta and accumulated selectively in the melanin structures of the fetal eyes. It was retained in the ocular tissues for five months after the drug had been eliminated from the rest of the body. There are no adequate and well-controlled studies evaluating the safety and efficacy of chloroquine in pregnant women.

    Nursing mothers

    Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential clinical benefit of the drug to the mother.

    The excretion of chloroquine and the major metabolite, desethylchloroquine, in breast milk was investigated in eleven lactating mothers following a single oral dose of chloroquine (600 mg base). The maximum daily dose of the drug that the infant can receive from breastfeeding was about 0.7% of the maternal start dose of the drug in malaria chemotherapy. Separate chemoprophylaxis for the infant is required.

    Geriatric use

    Clinical studies of Aralen did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.

    How to store:

  • Keep Aralen (Chloroquine Phosphate) tablets out of the sight and reach of children. This medicine could harm them.
  • Do not store your medicine above 30°C.
  • Protect the pills from light and moisture.
  • Keep this medicine in the container they came in.
  • Do not take Aralen after the expiry date stated on the carton. The expiry date refers to the last day of that month.

    Medications should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer required. This will help to protect the environment.

    Where to buy chloroquine online:

    To purchase Aralen (Chloroquine Phosphate) 250 mg, 500 mg tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.

    Here is a list of popular medications containing chloroquine phosphate as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

    Trade name of the drug Pharmaceutical forms and doses Companies
  • Tablets; Oral; 150 mg, 250 mg, 300 mg, 500 mg
  • Sanofi
  • Lariago
  • Injectable; Injection; 40 mg / ml
  • Suspension; Oral; 50 mg / 5 ml
  • Syrup; Oral; Chloroquine 80 mg / 5 ml
  • Tablets, Film-Coated; Oral; 250 mg
  • Ipca Laboratories
  • Malarex
  • Syrup; Oral; 120 mg / 5 ml
  • Tablets, Film-Coated; Oral; 250 mg
  • Alpharma
  • Actavis
  • Resochin
  • Injectable; Injection; 40 mg / ml
  • Suspension; Oral; 50 mg / 5 ml
  • Syrup; Oral; 50 mg / 5 ml, 100 mg / 5 ml
  • Tablets, Dispersible; Oral; 500 mg
  • Tablets, Film-Coated; Oral; 250 mg
  • Bayer
  • Kern Pharma

  • P O Box 602-C-3, Crown Hill, 1000 Monrovia 10, Liberia. Phones: +231-88-0658913, +231-88-6550494. Fax: +231-226-130/050/132. E-mail: [email protected]
    Copyright © 2006 - 2024 YMCA Liberia. All rights reserved.